Mirabella Financial Services LLP Increases Holdings in Stryker Corporation $SYK

Mirabella Financial Services LLP lifted its stake in shares of Stryker Corporation (NYSE:SYK) by 124.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,248 shares of the medical technology company’s stock after purchasing an additional 5,681 shares during the quarter. Mirabella Financial Services LLP’s holdings in Stryker were worth $3,781,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in SYK. Davis R M Inc. increased its holdings in shares of Stryker by 1.8% in the third quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock worth $51,285,000 after purchasing an additional 2,512 shares during the period. Terra Alpha Investments LLC purchased a new stake in shares of Stryker in the third quarter worth $1,216,000. Kepler Cheuvreux Suisse SA purchased a new position in Stryker during the third quarter worth about $27,952,000. Diversified Trust Co increased its stake in Stryker by 45.6% in the 3rd quarter. Diversified Trust Co now owns 12,445 shares of the medical technology company’s stock worth $4,601,000 after acquiring an additional 3,899 shares during the last quarter. Finally, SVB Wealth LLC purchased a new stake in shares of Stryker in the 2nd quarter valued at about $4,785,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of NYSE SYK opened at $345.64 on Thursday. The stock’s 50-day moving average is $364.43 and its 200 day moving average is $366.61. The stock has a market cap of $132.27 billion, a price-to-earnings ratio of 41.15, a P/E/G ratio of 2.04 and a beta of 0.85. Stryker Corporation has a 1-year low of $328.23 and a 1-year high of $404.87. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. During the same quarter in the prior year, the firm earned $4.01 earnings per share. Stryker’s revenue for the quarter was up 11.4% on a year-over-year basis. On average, sell-side analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s dividend payout ratio is 41.90%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the subject of several recent analyst reports. Sanford C. Bernstein boosted their price objective on Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Stryker in a research note on Monday, December 22nd. Truist Financial cut their price target on shares of Stryker from $400.00 to $392.00 and set a “hold” rating for the company in a research note on Thursday, December 18th. William Blair reissued an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Finally, TD Cowen cut shares of Stryker from a “buy” rating to a “hold” rating and set a $387.00 price objective on the stock. in a research report on Monday, January 26th. Fourteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $427.50.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.